Valuation: Positron Corporation

Market Cap 54.2M 49.2M 45.45M 41M 77.4M 5.06B 80.37M 548M 217M 2.73B 203M 199M 8.63B P/E 2024
-11x
P/E 2025 -4.87x
Enterprise Value 53.06M 48.17M 44.49M 40.14M 75.78M 4.96B 78.68M 536M 212M 2.68B 199M 195M 8.45B EV / Sales 2024
49.4x
EV / Sales 2025 116x
Free-Float
45.01%
Yield 2024 *
-
Yield 2025 -
1 day+0.15%
1 week-4.07%
Current month-3.05%
1 month+6.45%
3 months-4.07%
6 months-15.17%
Current year-1.20%
1 week 1.63
Extreme 1.63
1.72
1 month 1.57
Extreme 1.57
1.8
Current year 1.43
Extreme 1.43
2.74
1 year 1.27
Extreme 1.27
2.74
3 years 0.87
Extreme 0.87
2.94
5 years 0.07
Extreme 0.0682
2.94
10 years 0
Extreme 0
2.94
Manager TitleAgeSince
Director of Finance/CFO 53 -
Sales & Marketing - 23/06/2022
Corporate Officer/Principal 40 24/05/2018
Director TitleAgeSince
Chairman 53 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%-4.07%+4.43%+65.00% 54.11M
-0.66%-4.37%+21.09%+47.25% 256B
-1.80%-4.38%+2.42%+8.66% 162B
-1.65%-4.34%-21.25%+41.03% 152B
-1.51%-3.74%-57.71%-20.81% 63.33B
-1.57%+1.37%+24.42%+57.59% 61.59B
-1.59%+0.84%+3.64%-13.47% 53.86B
-0.40%-3.18%+19.17%+52.21% 48.75B
-3.63%-5.61%+4.12%+63.37% 48.46B
-0.80%-5.41%+19.00%+71.75% 44.56B
Average -1.35%-2.31%+1.93%+37.26% 89B
Weighted average by Cap. -1.37%-2.99%+2.91%+33.75%

Financials

2024 2025
Net sales 588K 533K 493K 444K 839K 54.89M 871K 5.94M 2.35M 29.62M 2.2M 2.16M 93.58M 461K 419K 387K 349K 659K 43.11M 684K 4.66M 1.84M 23.26M 1.73M 1.69M 73.51M
Net income -2.38M -2.16M -2M -1.8M -3.4M -222M -3.53M -24.04M -9.51M -120M -8.93M -8.74M -379M -10.6M -9.63M -8.89M -8.02M -15.14M -991M -15.72M -107M -42.38M -535M -39.78M -38.95M -1.69B
Net Debt 1.42M 1.29M 1.19M 1.08M 2.03M 133M 2.11M 14.39M 5.69M 71.81M 5.34M 5.23M 227M -1.14M -1.03M -953K -860K -1.62M -106M -1.68M -11.48M -4.54M -57.28M -4.26M -4.17M -181M
Projected Income Statement - Annual - Positron Corporation
Logo Positron Corporation
Positron Corporation is a medical technology company focused to advancing the Positron Emission Tomography (PET) imaging modality through the development, manufacturing, and commercialization of its PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems along with providing comprehensive clinical services to nuclear medicine healthcare providers across North America. The Company specializes in the field of cardiac PET imaging, the gold standard in cardiac diagnostics. The Company’s imaging portfolio includes dedicated PET and 3D PET-CT 64-Slice systems, both designed to expand access to advanced molecular imaging. Additionally, it is preparing to introduce its 4D PET-CT 64-Slice scanner in nuclear cardiology. Its products, Attrius PET and NeuSight PET-CT 64- Slice scanner, provide a molecular imaging solution, enabling healthcare providers with diagnostic accuracy for cardiac and oncologic applications.
Employees
10
Date Price Change Volume
17/11/26 US$1.650 +0.15% 9,249
16/11/26 US$1.648 +0.46% 1,127
13/11/26 US$1.640 -2.96% 9,943
12/11/26 US$1.690 -6.11% 3,324
11/11/26 US$1.800 +4.65% 12,385
  1. Stock Market
  2. Stocks
  3. POSC Stock